[go: up one dir, main page]

WO2000067733A3 - Medicament pour traiter l'infertilite masculine - Google Patents

Medicament pour traiter l'infertilite masculine Download PDF

Info

Publication number
WO2000067733A3
WO2000067733A3 PCT/EP2000/003937 EP0003937W WO0067733A3 WO 2000067733 A3 WO2000067733 A3 WO 2000067733A3 EP 0003937 W EP0003937 W EP 0003937W WO 0067733 A3 WO0067733 A3 WO 0067733A3
Authority
WO
WIPO (PCT)
Prior art keywords
medicament
disturbances
treating human
human infertility
infertility
Prior art date
Application number
PCT/EP2000/003937
Other languages
German (de)
English (en)
Other versions
WO2000067733A2 (fr
Inventor
Claus Rolf
Eberhard Nieschlag
Original Assignee
Claus Rolf
Eberhard Nieschlag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Claus Rolf, Eberhard Nieschlag filed Critical Claus Rolf
Priority to AU44037/00A priority Critical patent/AU4403700A/en
Publication of WO2000067733A2 publication Critical patent/WO2000067733A2/fr
Publication of WO2000067733A3 publication Critical patent/WO2000067733A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/04—Nitro compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne l'utilisation de substances ayant une action stimulante sur le SNC pour produire des médicaments pour traiter l'infertilité, les troubles orgasmiques et les troubles de l'éjaculation chez l'homme. L'invention concerne également un procédé permettant de traiter l'infertilité, les troubles orgasmiques et les troubles de l'éjaculation chez l'homme, qui se fonde sur l'administration de substances à action stimulante du SNC.
PCT/EP2000/003937 1999-05-05 2000-05-03 Medicament pour traiter l'infertilite masculine WO2000067733A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU44037/00A AU4403700A (en) 1999-05-05 2000-05-03 Medicament for treating human infertility

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE1999120491 DE19920491A1 (de) 1999-05-05 1999-05-05 Medikament zur Therapie der männlichen Infertilität
DE19920491.8 1999-05-05

Publications (2)

Publication Number Publication Date
WO2000067733A2 WO2000067733A2 (fr) 2000-11-16
WO2000067733A3 true WO2000067733A3 (fr) 2002-02-28

Family

ID=7906927

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2000/003937 WO2000067733A2 (fr) 1999-05-05 2000-05-03 Medicament pour traiter l'infertilite masculine

Country Status (3)

Country Link
AU (1) AU4403700A (fr)
DE (1) DE19920491A1 (fr)
WO (1) WO2000067733A2 (fr)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0248215A2 (fr) * 1986-06-03 1987-12-09 Apotheker Popp oHG Médicament à action dopaminergique

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0248215A2 (fr) * 1986-06-03 1987-12-09 Apotheker Popp oHG Médicament à action dopaminergique

Non-Patent Citations (16)

* Cited by examiner, † Cited by third party
Title
CANADIAN JOURNAL OF PSYCHIATRY. REVUE CANADIENNE DE PSYCHIATRIE, (1998 AUG) 43 (6) 644-5. *
CLINICAL PHARMACOLOGY AND THERAPEUTICS, (1997 APR) 61 (4) 476-87. *
CNS DRUGS, (1996) 6/3 (204-216). *
DATABASE CHEMABS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; COLAO, ANNAMARIA ET AL: "Chronic treatment with CV 205-502 restores the gonadal function in hyperprolactinemic males", XP002154548, retrieved from STN Database accession no. 126:69946 CA *
DATABASE CHEMABS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; DALLO, JANOS ET AL: "The ejaculatory behavior of sexually sluggish male rats treated with (-)deprenyl, apomorphine, bromocriptine and amphetamine", XP002154546, retrieved from STN Database accession no. 106:188846 *
DATABASE CHEMABS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; KAPLAN, JOEL M. ET AL: "Apomorphine induces ejaculation in chronic decerebrate rats", XP002154545, retrieved from STN Database accession no. 115:175782 *
DATABASE CHEMABS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; PAGLIETTI, E. ET AL: "Apomorphine and L-DOPA lower ejaculation threshold in the male rat", XP002154547, retrieved from STN Database accession no. 89:84720 *
DATABASE EMBASE [online] ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL; WALDINGER M.D.: "Use of psychoactive agents in the treatment of sexual dysfunction.", XP002154544, retrieved from STN Database accession no. 96284656 *
DATABASE MEDLINE [online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; ASHTON A K ET AL: "Bupropion as an antidote for serotonin reuptake inhibitor-induced sexual dysfunction.", XP002154551, retrieved from STN Database accession no. 1998200223 *
DATABASE MEDLINE [online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; LABBATE L A: "Bupropion-SR-induced increased libido and spontaneous orgasm [letter].", XP002154549, retrieved from STN Database accession no. 1998399394 *
DATABASE MEDLINE [online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; MODELL J G ET AL: "Comparative sexual side effects of bupropion, fluoxetine, paroxetine, and sertraline.", XP002154550, retrieved from STN Database accession no. 97275795 *
EUR. J. ENDOCRINOL. (1996), 135(5), 548-552, 1996 *
JOURNAL OF CLINICAL PSYCHIATRY, (1998 MAR) 59 (3) 112-5. *
NEUROSCI. LETT. (1991), 129(2), 205-8 *
PHYSIOL. BEHAV. (1978), 20(5), 559-62 *
POL. J. PHARMACOL. PHARM. (1986), 38(3), 251-5 *

Also Published As

Publication number Publication date
DE19920491A1 (de) 2000-11-16
AU4403700A (en) 2000-11-21
WO2000067733A2 (fr) 2000-11-16

Similar Documents

Publication Publication Date Title
MX9700082A (es) Composicion que consiste de morfina, polipirrolidona y oxido de polialquileno.
HUP0104909A3 (en) 2-amino-benzoxazinone derivatives for the treatment of obesity, process for their preparation and medicaments containing them
NO954996L (no) Anvendelse av nona- og dekapeptider for fremstilling av et legemiddel for behandling av AIDS
AU2732001A (en) Apparatus and method of treatment of wounds, burns and immune system disorders
MY125978A (en) Admantane derivatives
AU3206299A (en) Method and apparatus for combining injury-mediated therapy and drug delivery
HUP0301333A3 (en) Pharmaceutical superdisintegrant, process for its preparation and its use
GB9521608D0 (en) Pharmaceutical composition
HK1040980A1 (zh) 聯苯磺酰基氨基氰、其製備方法及其作為藥物的用途
WO1998026770A3 (fr) Utilisation locale d'agonistes opioïdes kappa dans le traitement de la douleur oculaire
AU5170499A (en) Use of ginkgo biloba extracts for preparing a medicine for treating amyotrophic lateral sclerosis
WO2000008007A3 (fr) Derives de cyclopentabenzofuranne et leur utilisation
WO1994025012A3 (fr) Medicaments pour le traitement de la migraine, de l'epilepsie et des troubles de l'alimentation
ZA200107143B (en) Use of saredutant and the pharmaceutically acceptable salts thereof to produce medicaments used to treat or prevent mood disorders, adjustment disorders or mixed anxiety-depression disorders.
AU2001295979A1 (en) Medicinal compositions, dose and method for treating malaria
ZA200007111B (en) Methods and devices for providing prolonged drug therapy.
WO2000061125A3 (fr) L'osanetant dans le traitement des troubles de l'humeur
WO2000067733A3 (fr) Medicament pour traiter l'infertilite masculine
PL367401A1 (en) Utilization of buprenorphine in urinary incontinence therapy
IL126158A0 (en) Method for treating substance abuse
WO2000051585A3 (fr) Augmentation du volume osseux par utilisation d'agonistes selectifs d'ep1 n'existant pas naturellement
UA36251A (uk) Спосіб комплексної терапії простої шизофренії
EP0643060A3 (fr) Benzimadazoles substituées par sulfonylbenzyle, procédé pour leur préparation, et leur application en tant que médicaments.
HK1034505A1 (en) Triazepinones, process for their preparation and their therapeutic application.
UA34303A (uk) Спосіб лікування міокардиту

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 69(1) EPC.(EPO COMMUNICATION FORM 1205 HAS BEEN SENT ON 20/12/2002)

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP